Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Profusa ( (PFSA) ) is now available.
On February 11, 2026, Profusa entered into an exclusive worldwide know-how license agreement with Mayo Foundation for Medical Education and Research, securing patent rights and non-exclusive access to related know-how for continuous oxygen measurement tools and Critical Limb-Threatening Ischemia applications, including the Lumee product line. The deal, announced publicly on February 12, 2026, includes royalties, milestones, and sublicense revenue sharing, and establishes a collaboration with Mayo Clinic to investigate high-impact clinical uses in cardiovascular, renal, multi-organ, orthopedic, and postoperative perfusion monitoring, while supporting U.S. commercialization of Lumee for critical limb ischemia and expanding Profusa’s oxygen monitoring technology into new indications, with Mayo retaining a financial interest to fund its not-for-profit mission.
The agreement is structured to run until the later of key patent expirations or 15 years after the first commercial sale of the last licensed product, at which point the license becomes fully paid-up if Profusa meets its obligations. By aligning Profusa’s first-of-its-kind continuous tissue oxygen sensing platform with Mayo’s clinical expertise and investigator access, the partnership enhances Profusa’s regulatory and commercialization prospects in oxygen monitoring and could strengthen its competitive position in the digital health and biosensor markets while creating new revenue streams for both parties.
More about Profusa
Profusa, Inc., based in Berkeley, Calif., is a commercial-stage digital health company developing tissue-integrated, long-lasting injectable biosensors and an intelligent data platform to continuously transmit medical-grade biochemical data for personal and clinical use. Its flagship Lumee technology focuses on continuous tissue oxygen monitoring, targeting large unmet clinical needs and supporting more cost-efficient disease management across global healthcare systems.
Average Trading Volume: 367,175
Technical Sentiment Signal: Sell
Current Market Cap: $3.62M
For detailed information about PFSA stock, go to TipRanks’ Stock Analysis page.